Comparative Pharmacology
Head-to-head clinical analysis: ADALAT CC versus CARDENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADALAT CC versus CARDENE.
ADALAT CC vs CARDENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.
Cardene (nicardipine) is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It dilates peripheral arterioles, reducing systemic vascular resistance and blood pressure, and also has coronary vasodilatory effects.
30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.
20-40 mg orally three times daily.
None Documented
None Documented
Terminal elimination half-life: 7-10 hours; clinical context: sustained-release formulation provides therapeutic concentrations over 24 hours with once-daily dosing, but half-life does not directly reflect drug effect duration due to slow absorption.
1.5-2 hours (terminal); prolonged in hepatic impairment (up to 6-8 hours)
Renal: 70-80% as metabolites, fecal: 15-20% as metabolites, biliary: minimal (<5% unchanged).
Renal: 60% as metabolites, 10% unchanged; Fecal: 35%
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker